Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells (Talikabtagene Autoleucel) in Patients With Relapsed/Refractory B-Cell Malignancies (NexCAR19)

NCT07502118 is registered in ClinicalTrials.gov with Health Institutes of Turkey as lead sponsor.

NCT NCT07502118
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07502118 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells (Talikabtagene Autoleucel) in Patients With Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Lead sponsor
Health Institutes of Turkey
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 11, 2025
Completion date
January 1, 2030
Enrollment
40 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma (dlbcl), follicular lymphoma ( fl), high-grade b-cell lymphoma (hgbcl), relapsed/refractory b-cell acute lymphoblastic leukemia (b-all), relapsed/refractory non-hodgkin lymphoma